Physicians' Academy for Cardiovascular Education

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

Addressing CV risk: the role of statins and ezetimibe

5' education - Feb. 9, 2020 - Prof. Christopher Cannon, MD

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI

5' education - Feb. 2, 2020 - Baris Gencer, MD

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations

10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD

HFpEF: A misunderstood disease in search of a therapy

10' education - Jan. 23, 2020 - Prof. Scott Solomon

The safety of PCSK9 inhibitors - how low can we go?

5' education - Jan. 22, 2020 - Robert Giugliano, MD

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Translating ESC/EAS Dyslipidemia Guidelines to clinical practice

10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD
Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

Prof. Ray explains how he decides on the amount of LDL-c lowering that is needed in a given patient, and why he chooses this approach.

SGLT2i reduces atrial fibrillation and atrial flutter in T2DM

Literature - Feb. 17, 2020 - Zelniker TA et al. - Circulation 2020

The SGLT2 inhibitor dapagliflozin reduced time to first event of atrial fibrillation and atrial flutter as well as total events in T2DM patients, shown in a post-hoc analysis of the DECLARE-TIMI 58 trial.

Eating more processed meat, unprocessed red meat or poultry associated with incident CVD

Literature - Feb. 17, 2020 - Zhong VW et al., - JAMA Intern Med. 2020.
Higher intake of processed meat, unprocessed red meat or poultry was significantly associated with a small increased risk of incident CVD. Higher intake of processed meat or unprocessed red meat was also significantly associated with a small increased risk of all-cause mortality.

Higher intake of processed meat, unprocessed red meat or poultry was associated with a small increased risk of incident CVD. For all-cause mortality, a small increased risk was observed with higher intake of processed meat or unprocessed red meat.

Assessing residual lipid risk with advanced testing

5' education - Feb. 17, 2020 - Samia Mora, MD
Which lipids/lipoproteins, besides LDL-c, play a role in determining CV risk and can help targeting therapy in those with residual lipid risk?

Which lipids/lipoproteins, besides LDL-c, play a role in determining CV risk and can help targeting therapy in those with residual lipid risk?

Large resting heart rate variability between individuals, but small variability within individuals

Literature - Feb. 13, 2020 - Quer G et al., - PLoS ONE 2020

This retrospective observational study using heart rate (HR) data from wearable devices found that average resting HR varies widely between individuals, but is more consistent over time within individuals.

Sustained efficacy and safety of PCSK9 antibody in HoFH and severe HeFH

Literature - Feb. 12, 2020 - Santos RD et al., - J Am Coll Cardiol. 2020

The open-label TAUSSIG study evaluated treatment with evolocumab during a median follow-up of 4.1 years and found a similar safety profile and good LDL-c lowering in HoFH and HeFH patients

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME
Prof. Bhatt gives an in-depth overview of the REDUCE-IT trial, in which the effect of icosapent ethyl, a highly purified form of EPA, on CV outcomes was studied.

Prof. Bhatt gives an in-depth overview of the REDUCE-IT trial, in which the effect of icosapent ethyl, a highly purified form of EPA, on CV outcomes was studied. WIth question to test your knowledge.

Baseline HbA1c levels associated with CV outcomes in high risk T2DM patients

Literature - Feb. 10, 2020 - Menon V et al., - J Am Heart Assoc. 2020.

This subanalysis of the ACCELERATE trial showed that HbA1c levels at study baseline are associated with CV outcomes in T2DM patients with a history of coronary artery disease and on optimal medical therapy.

Initiating CV preventive medication affects lifestyle in positive and negative ways

Literature - Feb. 10, 2020 - Korhonen MJ et al., - J Am Heart Assoc. 2020

Adults who started primary CV preventive pharmacotherapy showed higher BMI and more inactivity, but reduced smoking and alcohol consumption after about 4 years than those not taking drugs.

No association between HDL particle concentration and MACE after ACS

Salahuddin T, et al.

Literature - Feb. 10, 2020 - Am Heart J 2019

An analysis of data of the dal-OUTCOMES trial shows that concentration of HDL particles is not associated with risk of MACE in patients after ACS.

Addressing CV risk: the role of statins and ezetimibe

5' education - Feb. 9, 2020 - Prof. Christopher Cannon, MD
Prof. Cannon presents clinical studies demonstrating that lower LDL-c with use of statins and ezetimibe decreases CV risk. Unfortunately, studies using registries show that these agents are often not used.

Prof. Cannon presents clinical studies demonstrating that lower LDL-c with use of statins and ezetimibe decreases CV risk. Unfortunately, studies using registries show that these agents are often not used.

Screening for diabetes in black barbershops

Literature - Feb. 5, 2020 - Osorio M et al., - JAMA Intern Med. 2020.

This study evaluated a community-based screening approach in 8 barbershops in Brooklyn, New York and found a prevalence of undiagnosed diabetes in 9.0% of the black male participants.

Agenda